Clinical Research Directory

Inclusion Criteria: * Dialysis vintage ≥ 3 months * Treatment schedule of 3x4 hours weekly * well functioning dual lumen vascular access * Treatment with ASA 80-100mg daily * Patients able and agree to provide signed informed consent Exclusion Criteria: * Known vascular access dysfunction defined by FOR CATHETER ACCESS: high dose urokinase use within 4 weeks prior to study participation, planned catheter opacification, Qb \<250mL/min within the 2 weeks prior to study participation FOR AV ACCESS: planned AV access intervention, recent AV access intervention within 4 weeks prior to study participation, known AV access dysfunction * Known active malignancy and/or active autoimmune disease * Known clotting/bleeding disorders * Current treatment with immunosuppressive medication * Current treatment with P2Y12 receptor antagonists (including clopidogrel, prasugrel, ticlodipine, cangrelor, ticagrelor), epoprostenol and glycoproteine IIb/IIIa receptor antagonists (tirofiban) * Current treatment with oral anticoagulation maintenance therapy, including vitamin K antagonists or direct oral anticoagulants * Current treatment with low molecular weight heparins (LMWH), heparinoids, bivalirudin, fondaparinux, protein C, or antithrombin. * Active infection and/or ongoing systemic antimicrobial treatment. * Hospitalized patients * Patients treated with heparin-free hemodialysis * Recent (\<1 week) platelet transfusion or packed cells transfusion * Patients receiving intradialytic TPN * Patients requiring intravenous iron administration during dialysis (EPO or Parsabiv administration will be postponed until after disconnection from the dialysis circuit and after T240 blood sampling). * Patients with cytopenia affecting either white blood cells (WBC \< 4x10³/mm³) or platelets defined as (platelet counts \<100x10³/mm³) * Patients known to have had allergic reactions to PS, PMMA or ATA dialyzer